Completed
NA
INTERVENTIONAL
NCT04500743
Role of Suppression of Endometriosis With Progestins Before IVF-ET
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This study aimed to assess the role of Dienogest pretreatment for endometriosis suppression as compared to Gonadotropin-releasing hormone agonist (GnRHa) in patients with endometriosis pursuing IVF treatment.
Interventions
Name:
Dienogest
Type:
DRUG
Description:
Group B (n=67) who had daily oral Dienogest 2 mg/d for 3 months before starting standard long protocol for IVF
Name:
leuprorelin acetate
Type:
DRUG
Description:
Group A (n=67) who had monthly depot GnRHa for 3 months before ovarian stimulation in IVF treatment (Ultra-long protocol)
Primary Outcomes
Measure:
the number of retrieved oocytes
TimeFrame:
After the ovarian induction (3 months after the pre treatment with either GnRHa or Dienogest)
Description:
the number of retrieved oocytes as the main concern was the effect of either GnRHa or Dienogest on ovarian responsiveness
Trial Information
NCT ID
NCT04500743
Status
Completed
Study Type
INTERVENTIONAL
Phases
NA
Sponsor
National Research Centre, Egypt
Last Updated
December 15, 2025